LR

Laurens Rademacher

Chief Technology Officer

EMERGEX VACCINES HOLDING LIMITED

Oxford, England


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
EMERGEX VACCINES HOLDING LIMITED
Industry
research
Employees
40.0
Seniority
C suite
Total Funding
12328110.0
Latest Funding
Series A

Technologies

Outlook Microsoft Office 365 Google Font API Google Maps WordPress.org Apache Typekit Mobile Friendly

Keywords

biotechnology research t cell-priming vaccine immunotherapy synthetic vaccines infectious diseases cellular immune responses long-lasting immunity nanotechnology microneedle delivery patch-based therapeutics assembly of t cells vaccine development dengue fever betacoronavirus universal influenza clinical trials antigen presenting cells public health immunoproteomics multi-omic technologies mhc class i pathogen-derived peptides viral peptides intradermal administration gmp manufacturing immunization compliance pathogen response chikungunya virus t cell immunity safety profile cold chain requirements cd8+ t cells vaccine technology immune system activation synthetic immunity dendritic cell activation biosecurity emergency vaccine development medical countermeasures clinical research therapeutic vaccines global health prevention strategies healthcare innovation long-term protection viral infections pharmaceutical partnering health care health wellness & fitness hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans